Low-dose decitabine and high-risk MDS [1]

Blood

Volumn 108, Issue 13, 2006, Pages 4291-

  Raza, Azra ^a   Raza, Fatima Zehra ^b   Galili, Naomi ^b  

^a UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; AZCITIDINE; IMMUNOSUPPRESSIVE AGENT; PROTEIN P15;

CHRONIC MYELOID LEUKEMIA; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; HOSPITALIZATION; HUMAN; INCIDENCE; LETTER; LOW DRUG DOSE; METHYLATION; MYELODYSPLASTIC SYNDROME; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; RANDOMIZED CONTROLLED TRIAL; RISK FACTOR;

EID: 33845505652     PISSN: 00064971     EISSN: 00064971     Source Type: Journal    
DOI: 10.1182/blood-2006-08-041145     Document Type: Letter

References (2)

1. Kantarjian H, Oki Y, Garcia-Manero G, et al. Results of a randomized study of three schedules of low-dose decitabine in higher risk myelodysplastic syndrome and chronic myelomonocytic leukemia. Blood. Prepublished online August 1, 2006, as DOI 10.1182/blood-2006-05-021162.
2. Aoki E, Uchida T, Ohashi H, et al. Methylation status of the p15INK4B gene in hematopoietic progenitors and peripheral blood cells in myelodysplastic syndromes. Leukemia. 2000;14:589-593.